Literature DB >> 23258775

High prevalence of occult left heart disease in scleroderma-pulmonary hypertension.

Benjamin D Fox1, Avi Shimony, David Langleben, Andrew Hirsch, Lawrence Rudski, Robert Schlesinger, Mark J Eisenberg, Dominique Joyal, Marie Hudson, Kim Boutet, Alexandrina Serban, Ariel Masetto, Murray Baron.   

Abstract

Our study aimed to determine the prevalence of occult left-heart disease in patients with scleroderma and pulmonary hypertension. In patients with pulmonary hypertension (mean pulmonary artery pressure (mean PAP)≥25 mmHg), differentiation between pre- and post-capillary pulmonary hypertension has been made according to pulmonary artery wedge pressure (PAWP) less than or more than 15 mmHg, respectively. We performed a retrospective chart review of 107 scleroderma patients. All patients with suspected pulmonary hypertension had routine right or left heart catheterisation with left ventricular end-diastolic pressure (LVEDP) measurement pre-/post-fluid challenge. We extracted demographic, haemodynamic and echocardiographic data. Patients were classified into one of four groups: haemodynamically normal (mean PAP<25 mmHg); pulmonary venous hypertension (PVH) (mean PAP≥25 mmHg, PAWP>15 mmHg); occult PVH (mean PAP≥25 mmHg, PAWP≤15 mmHg, LVEDP>15 mmHg before or after fluid challenge); and pulmonary arterial hypertension (PAH) (mean PAP≥25 mmHg, PAWP≤15 mmHg and LVEDP≤15 mmHg before or after fluid challenge). 53 out of 107 patients had pulmonary hypertension. Based on the PAWP-based definition, 29 out of 53 had PAH and 24 out of 53 had PVH. After considering the resting and post-fluid-challenge LVEDP, 11 PAH patients were reclassified as occult PVH. The occult PVH group was haemodynamically, echocardiographically and demographically closer to the PVH group than the PAH group. PVH had high prevalence in our scleroderma-pulmonary hypertension population. Distinguishing PAH from PVH with only PAWP may result in some PVH patients being misclassified as having PAH.

Entities:  

Mesh:

Year:  2012        PMID: 23258775     DOI: 10.1183/09031936.00091212

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  34 in total

1.  Variability in hemodynamic evaluation of pulmonary hypertension at large referral centers.

Authors:  Meredith E Pugh; Anna R Hemnes; Aaron Trammell; John H Newman; Ivan M Robbins
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

2.  Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort.

Authors:  Matthew R Lammi; Lesley A Saketkoo; Jessica K Gordon; Paula Lauto; Karen Fagan; Virginia D Steen
Journal:  Respirology       Date:  2017-05-12       Impact factor: 6.424

3.  Pulmonary Edema Following Initiation of Parenteral Prostacyclin Therapy for Pulmonary Arterial Hypertension: A Retrospective Study.

Authors:  Nauman A Khan; Rizwan A Khan; Adriano R Tonelli; Kristin B Highland; Neal F Chaisson; Miriam Jacob; Rahul Renapurkar; Raed A Dweik; Gustavo A Heresi
Journal:  Chest       Date:  2019-02-15       Impact factor: 9.410

4.  High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension.

Authors:  Ivan M Robbins; Anna R Hemnes; Meredith E Pugh; Evan L Brittain; David X Zhao; Robert N Piana; Pete P Fong; John H Newman
Journal:  Circ Heart Fail       Date:  2013-12-02       Impact factor: 8.790

Review 5.  WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension.

Authors:  Sif Hansdottir; Dayna J Groskreutz; Brian K Gehlbach
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

6.  Hemodynamic heterogeneity of connective tissue disease patients with borderline mean pulmonary artery pressure and its distinctive characters from those with normal pulmonary artery pressure: a retrospective study.

Authors:  Yusa Asari; Yoshioki Yamasaki; Kosei Tsuchida; Kengo Suzuki; Yoshihiro J Akashi; Takahiro Okazaki; Shoichi Ozaki; Hidehiro Yamada; Kimito Kawahata
Journal:  Clin Rheumatol       Date:  2018-05-18       Impact factor: 2.980

Review 7.  Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials.

Authors:  Marc Humbert; Manjit Singh; Daniel E Furst; Dinesh Khanna; James R Seibold
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

Review 8.  Evolving Concepts of Pulmonary Hypertension Secondary to Left Heart Disease.

Authors:  Bhavadharini Ramu; Thenappan Thenappan
Journal:  Curr Heart Fail Rep       Date:  2016-04

Review 9.  Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).

Authors:  Vincent Sobanski; David Launay; Eric Hachulla; Marc Humbert
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

10.  Hemodynamic evidence of vascular remodeling in combined post- and precapillary pulmonary hypertension.

Authors:  Tufik R Assad; Evan L Brittain; Quinn S Wells; Eric H Farber-Eger; Stephen J Halliday; Laura N Doss; Meng Xu; Li Wang; Frank E Harrell; Chang Yu; Ivan M Robbins; John H Newman; Anna R Hemnes
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.